Scholar Rock Holding has ridden a powerful narrative this year around its muscle-targeted therapy for spinal muscular atrophy, capped by the U.S. launch of ISEMBYLD and a sharply higher share price. ...
Source LinkScholar Rock Holding has ridden a powerful narrative this year around its muscle-targeted therapy for spinal muscular atrophy, capped by the U.S. launch of ISEMBYLD and a sharply higher share price. ...
Source Link
Comments